Full resolution of psoriasis in half of ixekizumab patients

More than half of the patients treated with the interleukin-17A antagonist, ixekizumab, achieved full resolution of skin plaques after a year of 2- to 4-week dosing, according to the latest analysis of data from the three UNCOVER trials of almost 4,000 patients with moderate to severe...
Source: Skin and Allergy News - Category: Dermatology Source Type: news